Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 50,000 shares at $152.10 ($7.5M) on 2014-06-24, disclosed to the SEC on 2014-06-26.
Scheduled sale ($7.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $147.08 | 4,199 | $618K | 8.3% |
| 2 | $148.13 | 15,742 | $2.3M | 31.2% |
| 3 | $149.17 | 7,772 | $1.2M | 15.5% |
| 4 | $150.19 | 8,896 | $1.3M | 17.9% |
| 5 | $151.36 | 4,000 | $605K | 8.1% |
| 6 | $152.10 | 4,500 |
| $684K |
| 9.1% |
| 7 | $153.06 | 3,800 | $582K | 7.8% |
| 8 | $154.54 | 1,044 | $161K | 2.2% |
| 9 | $148.64 | 47 | $7K | 0.1% |
| Total | $149.69 avg | 50,000 | $7.5M | 100% |
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |